High-throughput, high-quality DNA and RNA purification for detection of multiple pathogens
Pathogen testing protocols (e.g. for COVID-19, influenza or easy-to-lyse bacterial pathogens) require fast, reliable, high-yield, high-quality and easily automatable sample preparation methods.
Our sbeadex™ Pathogen Nucleic Acid Purification Kits with their optimised chemistry meet these requirements and deliver excellent yields of highly purified nucleic acids from various sample material that can be used in many downstream applications such as PCR/qPCR, RT-PCR/qRT-PCR, and NGS. The purification procedure can be fully automated and is compatible with many robotic platforms.
The sbeadex Pathogen Nucleic Acid Purification Kit is a simple renaming of our proven sbeadex Viral RNA Purification Kit to reflect its continuously expanding usability to purify good yields of high-quality DNA and RNA from a variety of viral, bacterial and yeast pathogens.
Please see Table 1 for a list of viral, bacterial and yeast pathogens and compatible matrices that have been tested so far.
For Research Use Only. Not for use in diagnostic procedures.

Key benefits
- Qualified protocol for viral and bacterial nucleic acid purification
- Compatible with most popular robotic platforms, including the Kingfisher™ and our high-throughput oKtopure™ instrument
- Fast – both short (25 min) and standard (45 min) protocols available
- High-throughput batch sizes (up to 10,000 purifications)
- No organic extraction, alcohol precipitation or centrifugation steps
- Water-based wash buffers reduce solvent carryover, resulting in absence of PCR inhibitors in final eluate
- High nucleic acid quality for all downstream applications including PCR/qPCR and NGS
- Ready-to-use kits with high stability (customised and bulk size kits are also available)
Pathogen | External Control (Artificial Matrix) |
---|---|
Viral Targets | |
SARS-CoV-2 | VTM1 |
Influenza A H3N2 | Swab2 |
Influenza B | Swab2 |
Novel Influenza A H1N1 | Swab2 |
Respiratory Syncytial Virus (subtype A) | Swab2 |
Respiratory Syncytial Virus (subtype B) | Swab2 |
Adenovirus 4 | Swab2 |
Zika Virus | Plasma3 |
Cytomegalovirus | Plasma4 |
Human Papillomavirus-16 | Methanol-preserved cultured human cells containing full-length HPV episomal DNA5 |
Bacterial Targets | |
Bordetella pertussis | Swab6 |
Chlamydophila pneumoniae | Swab6 |
Chlamydophila psittaci | Swab6 |
Coxiella burnetii | Swab6 |
Legionella pneumophila | Swab6 |
Mycoplasma pneumoniae | Swab6 |
Mycobacterium tuberculosis | Sputum7 |
Campylobacter jejuni | Stool8 |
Salmonella enteritidis | Stool8 |
Yersinia enterocolitica | Stool8 |
Clostridium difficile | Stool8 |
Chlamydia trachomatis | Urine9 |
Neisseria gonorrhoeae | Urine9 |
Staphylococcus aureus | External Run Control10 |
Other Targets | |
Candida albicans | Positive Extraction Control11 |
Compatible Matrices Tested | Swabs (UTM®/VTM) Sputum Saliva Blood Plasma Serum Urine Stool Cerebrospinal Fluid |
Table 1: Pathogens that have already been tested using the sbeadex Pathogen Nucleic Acid Purification Kit.
Standards used for testing
- AccuPlex™ SARS-CoV-2 Verification Panel - Full Genome, 0505-0168 (LGC SeraCare)
- AMPLIRUN® TOTAL RESPIRATORY VIRAL PANEL CONTROL (SWAB), MBTC020 (Vircell S.L.)
- AMPLIRUN TOTAL ZIKV/DENV/CHIKV CONTROL (PLASMA), MBTC023 (Vircell S.L.)
- AMPLIRUN TOTAL CMV CONTROL (PLASMA), MBTC018-R (Vircell S.L.)
- AccuTrak™ HPV Genotype Qualification Panel, QSH701 (2400-0161), (LGC SeraCare)
- AMPLIRUN TOTAL ATYPICAL BACTERIAL PNEUMONIA CONTROL (SWAB) MBTC022-R (Vircell S.L.)
- AMPLIRUN TOTAL MTB CONTROL (SPUTUM) MBTC013 (Vircell S.L.)
- AMPLIRUN TOTAL GASTROINTESTINAL BACTERIAL PANEL CONTROL (STOOL), MBTC021 (Vircell S.L.)
- AMPLIRUN TOTAL CT/NG CONTROL (URINE), MBTC003 (Vircell S.L.)
- NATtrol™ S. aureus (MRSA) External Run Control, NATSAU(MRSA)-ERCM (Zeptometrix Corporation)
- NATtrol Candida/TV Positive Control, NATCTVPOS-BD (Zeptometrix Corporation)
Note: Other sample matrices may also be used with this kit. Further testing on other pathogens and matrices is in progress and this table will be updated accordingly.
